Compare Dr. Reddys with Procter & Gamble Health - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

DR. REDDYS LAB vs PROCTER & GAMBLE HEALTH - Comparison Results

DR. REDDYS LAB     Change

Dr. Reddy's is a leading pharmaceutical company in the country with presence across the value chain. While the global generics business accounted for 69% of total revenues in FY12, the PSAI business (Pharma Services and Active Ingredients - PSAI) con... More

PROCTER & GAMBLE HEALTH 
   Change

Merck, the Indian arm of Merck KgaA (Germany), is a relatively smaller player among MNC pharma majors in the country. Merck has two business segments namely Pharmaceuticals and Chemicals. The pharmaceutical business, accounting for 68% of total sales... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    DR. REDDYS LAB PROCTER & GAMBLE HEALTH DR. REDDYS LAB/
PROCTER & GAMBLE HEALTH
 
P/E (TTM) x 21.3 52.2 40.8% View Chart
P/BV x 3.2 4.7 67.5% View Chart
Dividend Yield % 0.7 10.0 7.4%  

Financials

 DR. REDDYS LAB   PROCTER & GAMBLE HEALTH
EQUITY SHARE DATA
    DR. REDDYS LAB
Mar-19
PROCTER & GAMBLE HEALTH
Dec-18
DR. REDDYS LAB/
PROCTER & GAMBLE HEALTH
5-Yr Chart
Click to enlarge
High Rs2,8753,549 81.0%   
Low Rs1,8881,301 145.1%   
Sales per share (Unadj.) Rs930.2511.4 181.9%  
Earnings per share (Unadj.) Rs117.461.3 191.6%  
Cash flow per share (Unadj.) Rs185.874.0 251.0%  
Dividends per share (Unadj.) Rs20.00440.00 4.5%  
Dividend yield (eoy) %0.818.1 4.6%  
Book value per share (Unadj.) Rs844.4927.8 91.0%  
Shares outstanding (eoy) m166.0716.60 1,000.4%   
Bonus/Rights/Conversions ESOP--  
Price / Sales ratio x2.64.7 54.0%   
Avg P/E ratio x20.339.6 51.3%  
P/CF ratio (eoy) x12.832.8 39.1%  
Price / Book Value ratio x2.82.6 107.9%  
Dividend payout %17.0717.9 2.4%   
Avg Mkt Cap Rs m395,49640,257 982.4%   
No. of employees `00022.01.1 1,937.0%   
Total wages/salary Rs m33,5621,313 2,556.7%   
Avg. sales/employee Rs Th7,032.87,486.7 93.9%   
Avg. wages/employee Rs Th1,527.91,157.6 132.0%   
Avg. net profit/employee Rs Th887.7897.2 98.9%   
INCOME DATA
Net Sales Rs m154,4828,490 1,819.6%  
Other income Rs m3,375244 1,383.8%   
Total revenues Rs m157,8578,734 1,807.4%   
Gross profit Rs m31,7821,482 2,145.1%  
Depreciation Rs m11,348211 5,373.1%   
Interest Rs m8890-   
Profit before tax Rs m22,9201,514 1,513.6%   
Minority Interest Rs m00-   
Prior Period Items Rs m4380-   
Extraordinary Inc (Exp) Rs m066 0.0%   
Tax Rs m3,858563 685.9%   
Profit after tax Rs m19,5001,017 1,916.7%  
Gross profit margin %20.617.5 117.9%  
Effective tax rate %16.837.1 45.3%   
Net profit margin %12.612.0 105.3%  
BALANCE SHEET DATA
Current assets Rs m111,10115,343 724.1%   
Current liabilities Rs m58,9731,960 3,008.5%   
Net working cap to sales %33.7157.6 21.4%  
Current ratio x1.97.8 24.1%  
Inventory Days Days7949 162.8%  
Debtors Days Days9428 331.1%  
Net fixed assets Rs m101,2451,209 8,372.2%   
Share capital Rs m830166 500.0%   
"Free" reserves Rs m139,40615,235 915.0%   
Net worth Rs m140,23615,401 910.6%   
Long term debt Rs m22,0000-   
Total assets Rs m224,65617,595 1,276.8%  
Interest coverage x26.8NM-  
Debt to equity ratio x0.20-  
Sales to assets ratio x0.70.5 142.5%   
Return on assets %9.15.8 157.0%  
Return on equity %13.96.6 210.5%  
Return on capital %14.910.3 145.7%  
Exports to sales %00-   
Imports to sales %00-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m88,6731,636 5,419.1%   
Fx outflow Rs m19,1044,368 437.4%   
Net fx Rs m69,569-2,732 -2,546.6%   
CASH FLOW
From Operations Rs m28,704-1,304 -2,201.6%  
From Investments Rs m-7,72712,697 -60.9%  
From Financial Activity Rs m-21,326-301 7,096.8%  
Net Cashflow Rs m-31411,093 -2.8%  

Share Holding

Indian Promoters % 25.5 0.0 -  
Foreign collaborators % 0.0 51.8 -  
Indian inst/Mut Fund % 5.4 18.2 29.7%  
FIIs % 35.3 1.0 3,530.0%  
ADR/GDR % 18.5 0.0 -  
Free float % 15.3 29.1 52.6%  
Shareholders   75,885 28,591 265.4%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare DR. REDDYS LAB With:   FRESENIUS KABI ONCO.  DIVIS LABORATORIES  FULFORD INDIA  ALEMBIC PHARMA  ELDER PHARMA  

Compare DR. REDDYS LAB With:   ACTAVIS (US)  MYLAN (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Indian Indices Continue Momentum, Key Q2FY20 Results, and Top Cues in Focus Today(Pre-Open)

On Wednesday, Indian share markets traded on a volatile note throughout the day and ended marginally higher.

Related Views on News

PROCTER & GAMBLE HEALTH Announces Quarterly Results (1QFY20); Net Profit Up 34.3% (Quarterly Result Update)

Aug 13, 2019 | Updated on Aug 13, 2019

For the quarter ended June 2019, PROCTER & GAMBLE HEALTH has posted a net profit of Rs 441 m (up 34.3% YoY). Sales on the other hand came in at Rs 2 bn (up 6.1% YoY). Read on for a complete analysis of PROCTER & GAMBLE HEALTH's quarterly results.

PROCTER & GAMBLE HEALTH 2017-18 Annual Report Analysis (Annual Result Update)

Aug 8, 2019 | Updated on Aug 8, 2019

Here's an analysis of the annual report of PROCTER & GAMBLE HEALTH for 2017-18. It includes a full income statement, balance sheet and cash flow analysis of PROCTER & GAMBLE HEALTH. Also includes updates on the valuation of PROCTER & GAMBLE HEALTH.

MERCK Announces Quarterly Results (4QFY19); Net Profit Up 79.2% (Quarterly Result Update)

May 13, 2019 | Updated on May 13, 2019

For the quarter ended March 2019, MERCK has posted a net profit of Rs 407 m (up 79.2% YoY). Sales on the other hand came in at Rs 2 bn (down 23.3% YoY). Read on for a complete analysis of MERCK's quarterly results.

MERCK LTD Announces Quarterly Results (3QFY19); Net Profit Up 31.3% (Quarterly Result Update)

Mar 5, 2019 | Updated on Mar 5, 2019

For the quarter ended December 2018, MERCK LTD has posted a net profit of Rs 135 m (up 31.3% YoY). Sales on the other hand came in at Rs 2 bn (down 32.8% YoY). Read on for a complete analysis of MERCK LTD's quarterly results.

DR. REDDYS LAB Announces Quarterly Results (3QFY19); Net Profit Up 67.0% (Quarterly Result Update)

Feb 4, 2019 | Updated on Feb 4, 2019

For the quarter ended December 2018, DR. REDDYS LAB has posted a net profit of Rs 5 bn (up 67.0% YoY). Sales on the other hand came in at Rs 39 bn (up 0.8% YoY). Read on for a complete analysis of DR. REDDYS LAB's quarterly results.

More Views on News

Most Popular

My 3 Best Small-cap Stocks to Get Rich in this Market Rebound(Profit Hunter)

Oct 14, 2019

This is once in a decade opportunity to make a killing from smallcap rebound.

Finally, Is the Share Price of Yes Bank Ready for a Rebound?(The 5 Minute Wrapup)

Oct 7, 2019

Here's what every individual investor must know about Yes Bank...

The One Stock I Like in this Market(The 5 Minute Wrapup)

Oct 10, 2019

There are rare periods in markets when you get good quality stocks at attractive valuations. Is this one such period?

Rebound Riches Could be Yours With These Stocks(Profit Hunter)

Oct 4, 2019

The secret to multibagger is not big businesses, but great managements... Here's how to find them to make the most of once in a decade rebound opportunity.

5 Smart Money Stocks to Profit from the Market Rebound(The 5 Minute Wrapup)

Oct 11, 2019

Now is the time to put money in these 5 stocks to take advantage of the recovery in the economy and the markets.

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2020
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

DR. REDDYS LAB SHARE PRICE


Oct 16, 2019 (Close)

TRACK DR. REDDYS LAB

  • Track your investment in DR. REDDYS LAB with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

DR. REDDYS LAB 5-YR ANALYSIS

COMPARE DR. REDDYS LAB WITH

MARKET STATS